强化降糖对血管事件及死亡的影响:根据糖尿病诊断年龄和病程分层——ADVANCE试验
ADVANCE试验纳入11138例2型糖尿病患者,按诊断年龄(≤50、>50-60、>60岁)和病程(≤5、>5-10、>10年)分组,比较强化与标准降糖对血管结局的影响。强化降糖显著降低主要大血管和微血管复合终点风险(HR 0.90,95%CI 0.82-0.98),且各亚组间无显著异质性(诊断年龄P=0.86,病程P=0.47)。全因死亡、心血管死亡及主要血管事件各组分也观察到一致的治疗效应。
要点
- 强化降糖显著降低主要大血管和微血管复合终点风险(HR 0.90,95%CI 0.82-0.98)。
- 诊断年龄亚组(≤50、>50-60、>60岁)间治疗效应无显著异质性(P=0.86)。
- 糖尿病病程亚组(≤5、>5-10、>10年)间治疗效应无显著异质性(P=0.47)。
核心结论
- 强化降糖可能可推荐用于任何诊断年龄或糖尿病病程的患者。
研究设计与样本
- 研究纳入ADVANCE试验11138例参与者,按糖尿病诊断年龄(≤50、>50-60、>60岁)和糖尿病病程(≤5、>5-10、>10年)分类为亚组。
主要发现
- 强化降糖显著降低主要大血管和微血管复合终点风险(HR 0.90,95%CI 0.82-0.98)。
- 按诊断年龄定义的亚组间比例效应无显著异质性(P=0.86)。
- 按糖尿病病程定义的亚组间比例效应无显著异质性(P=0.47)。
- 全因死亡、心血管死亡及主要血管事件各组分也观察到类似一致的治疗效应。
临床怎么用
- 作者认为强化降糖可能可推荐用于任何诊断年龄或糖尿病病程的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the vascular effects of pursuing more versus less glucose lowering in patients with younger or older age at diabetes diagnosis, and with shorter or longer diabetes duration. RESEARCH DESIGN AND METHODS: We studied 11,138 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, classified into subgroups defined by age at diabetes diagnosis (≤50, >50-60, and >60 years) and diabetes duration (≤5, >5-10, and >10 years). RESULTS: Intensive glucose lowering significantly lowered the risk of the primary composite outcome of major macrovascular and microvascular events (hazard ratio 0.90, 95% CI 0.82-0.98) with no evidence of heterogeneity in the proportional effects across subgroups defined by age at diagnosis or diabetes duration (P for heterogeneity = 0.86 and 0.47, respectively). Similar consistent treatment effects were also observed for all-cause death, cardiovascular death, and the components of major vascular events. CONCLUSIONS: Intensive glucose lowering may be recommended irrespective of age at diagnosis or diabetes duration.
引用
- Ohkuma T, Harris K, Woodward M, et al. Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial. Diabetes Care. 2025. PMID: 39661106. doi:10.2337/dc24-1516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。